TY - JOUR AU - Kong, Yuan AU - Wu, Yi-Lin AU - Song, Yang AU - Shi, Min-Min AU - Cao, Xie-Na AU - Zhao, Hong-Yan AU - Qin, Ya-Zhen AU - Lai, Yue-Yun AU - Jiang, Hao AU - Jiang, Qian AU - Huang, Xiao-Jun PY - 2017 DA - 2017/08/30 TI - Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL JO - Journal of Translational Medicine SP - 184 VL - 15 IS - 1 AB - As one of the major treatment obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), relapse of Ph+ALL may result from the persistence of leukemia-propagating cells (LPCs). Research using a xenograft mouse assay recently determined that LPCs were enriched in the CD34+CD38−CD58− fraction in human Ph+ALL. Additionally, a cohort study demonstrated that Ph+ALL patients with a LPCs phenotype at diagnosis exhibited a significantly higher cumulative incidence of relapse than those with the other cell phenotypes even with uniform front-line imatinib-based therapy pre- and post-allotransplant, thus highlighting the need for novel LPCs-based therapeutic strategies. SN - 1479-5876 UR - https://doi.org/10.1186/s12967-017-1286-5 DO - 10.1186/s12967-017-1286-5 ID - Kong2017 ER -